Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,204 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07003555RecruitingPhase 1
Dual-target CAR-T therapy for multiple myeloma with extramedullary disease
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
ShanghaiAges 18–75 - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT07011056RecruitingPhase 3
Study of a new drug for diffuse large B-cell lymphoma
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
Chengdu, SichuanAges 18 years+ - NCT07012148Recruiting
Seizure forecasting with EEG and wearables for epilepsy
This study tests a wearable device that records brain waves to help predict and track seizures in people with temporal lobe epilepsy. It may help you better understand your seizure patterns and reduce uncertainty.
Rochester, MinnesotaAges 18–75 - NCT07014449RecruitingPhase 1
WBC100 capsule for relapsed or refractory AML
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07016997RecruitingPhase 1
A study of CBA-1535 for advanced solid tumors
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Nagaizumicho, ShizuokaAges 20 years+ - NCT07017686Recruiting
Reboot Study: Nerve stimulation for rheumatoid arthritis
This study tests a device that sends mild electrical pulses to the vagus nerve in the abdomen to treat rheumatoid arthritis. It is for people whose arthritis has not improved after trying multiple medications.
Fitzroy, VictoriaAges 18–75 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT07018050RecruitingPhase 2
A study of a new combination for multiple myeloma
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
TianjinAges 18 years+ - NCT07022197RecruitingPhase 1/Phase 2
BAFF-R CAR T cells for severe nerve and immune diseases
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT07031544Recruiting
Deep brain stimulation for severe OCD
This study tests whether implanting a small device deep in the brain—like a pacemaker for OCD—can help people whose severe OCD hasn't gotten better with standard medications and therapy.
Guangzhou, GuangdongAges 18–65 - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT07034924Recruiting
Abdominal tourniquet for severe postpartum bleeding
This trial tests a temporary abdominal tourniquet to stop heavy bleeding after childbirth when standard treatments aren't working. It might help women with severe blood loss avoid more invasive procedures.
ZaporizhzhiaAges 18–50 - NCT07048808RecruitingPhase 2
Gene therapy for chronic chest pain
This trial tests a new gene therapy (XC001) delivered through a thin tube into your heart's blood vessels. It aims to grow new blood vessels to relieve chest pain in people with chronic angina who have no other treatment options.
Cincinnati, OhioAges 18–85 - NCT07055477RecruitingPhase 1
CCR4 CAR T cells for T-cell lymphoma
This trial tests a new immunotherapy that targets a protein called CCR4 on certain T-cell lymphomas. The treatment uses your own immune cells, modified to find and attack cancer cells, and may help when other treatments have stopped working.
Bethesda, MarylandAges 18–120 - NCT07058298RecruitingEarly Phase 1
GC012F injection for hard-to-treat myasthenia gravis
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
Wuhan, HubeiAges 18–75 - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07066358Recruiting
Treating essential tremor with focused heat to both sides of the brain
This trial tests a one-time procedure that uses heat to stop the brain cells causing tremor. It might help people with severe shaking that hasn't improved with medication.
Shinjuku-Ku, TokyoAges 20–70 - NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new treatment called CTD402 for people with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to other treatments. It looks at whether adding a donor stem cell transplant after CTD402 can help control the disease.
Palo Alto, CaliforniaAges 12 years+ - NCT07070323RecruitingPhase 1/Phase 2
Nanobody CD5-CAR T cells for T-cell cancers
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Beijing, Beijing MunicipalityAges 1–70 - NCT07070518RecruitingPhase 1/Phase 2
Study of GV20-0251 for advanced solid tumors
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07072169RecruitingPhase 1
Testing an mRNA therapy for relapsed B-cell lymphoma
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,204 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.